Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Cardiology > Trials > Flashcards

Trials Flashcards

1
Q

This trial demonstrated no benefit and increased stroke risk for routine aspiration thrombectomy during PCI for STEMI

A

TOTAL (NEJM 2015)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

This trial demonstrated continuing warfarin through ICD/PPM implantation decreased pocket hematoma incidence compared to bridging with heparin

A

BRUISE CONTROL (NEJM 2013)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which statin is associated with decreased GFR and increased proteinuria and what trial showed that?

A

Rosuvastatin
PLANET trial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Anakinra MOA and trial for recurrent pericarditis

A

IL1-beta receptor antagonist
AIRTRIP (JAMA, 2016)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Rilonacept MOA and trial for recurrent pericarditis

A

IL1-alpha and IL1-beta cytokine trap
RHAPSODY (NEJM, 2021)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

This trial showed no benefit for pre-hospital ticagrelor vs in-cath lab ticagrelor for STEMI

A

ATLANTIC (NEJM, 2014)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

This trial showed dronedarone reduced composite 1* outcome CV hospitalization + death in patients with AF

A

ATHENA (NEJM, 2009)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Trial showing benefit of continuing GDMT in HFimpEF

A

TRED-HF
(Lancet 2019)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Omecamtiv mecarbil (cardiac myosin activator) phase III RCTs

A

GALACTIC-HF (NEJM 2020): OM reduced composite of HHF + CV death

METEORIC-HF (JAMA 2022): OM did not improve exercise capacity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What trial showed target resting HR <80 is noninferior to <110bpm in permanent AF

A

RACE II (NEJM, 2010)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

This trial showed dronedarone led to increased mortality and worsening HF in hospitalized HFrEF patients

A

ANDROMEDA
(NEJM, 2008)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

This trial showed rivaroxaban 2.5mg BID + ASA reduced MACE but increased major bleeding compared to ASA alone for patients with stable CAD and/or PAD.

A

COMPASS
(NEJM 2017)

MACE HR 0.76
Bleed HR 1.7

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

This trial showed that in symptomatic HF w/ EF >45% and BMI >30, semaglutide improved QoL (KCCQ) and led to 11% weight loss

A

STEP-HFpEF
(NEJM, 2023)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

When these two countries were removed from TOPCAT analysis, the study became + for spiro leading to reduced HHF in HFpEF

A

Russia + Georgia

(TOPCAT-Americas, Circ 2015)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

This trial showed finerenone reduced composite of CVD + WHF in symptomatic HF patients with LVEF >40%

A

FINEARTS-HF
(NEJM, 2024)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

This trial showed that in MI w/ LVEF >50%, beta-blockers did NOT reduce composite of ACM or new MI

A

REDUCE-AMI
(NEJM, 2024)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

This trial showed that in patients w/ BMI >27 and ASCVD without T2DM, semaglutide reduced MACE

A

SELECT
(NEJM, 2023)

18
Q

This trial showed that in symptomatic HF LVEF >45%, sac-val did NOT improve a composite of HHF + CVD

A

PARAGON-HF
(NEJM, 2019)

19
Q

This trial showed in symptomatic HF EF >40%, empagliflozin reduced a composite of time to 1st HHF or CVD (CVD non-sig)

A

EMPORER-Preserved
(NEJM, 2021)

20
Q

This trial showed in AF/AFL, apixaban improved mortality, bleeding, and stroke rates vs warfarin

A

ARISTOTLE
(NEJM, 2011)

21
Q

This trial showed in AF, rivaroxaban is non-inferior to warfarin for bleeding and stroke

A

ROCKET-AF
(NEJM, 2011)

22
Q

This trial showed in AF, dabigatran 150mg led to lower stroke rate and similar bleeding vs warfarin

A

RE-LY
(NEJM 2010)

Dabigatran 110mg did not reduce strokes vs warfarin

23
Q

This trial showed in ACS, ticagrelor reduced a composite of CVD, MI, or stroke compared to clopidogrel

A

PLATO
(NEJM 2009)

24
Q

This trial showed in NSTEMI pre-treating with prasugrel did not improve a MACE composite vs prasugrel at the time of PCI

A

ACCOAST
(NEJM, 2013)

25
Q

This trial showed in UA/NSTEMI treated medically, prasugrel did NOT improve MACE compared to clopidogrel

A

TRILOGY-ACS
(NEJM, 2012)

26
Q

This trial showed that in UA/NSTEMI undergoing PCI, prasugrel reduced MACE but increased bleeding vs clopidogrel

A

TRITON-TIMI-38
(NEJM 2007)

27
Q

This trial showed that in UA/NSTEMI, clopidogrel reduced MACE vs placebo

A

CURE
(NEJM 2001)

28
Q

This trial showed that in AF + stable CAD (ie, PCI or CABG >1yr ago), rivaroxaban monotherapy was non-inferior to rivarox+ASA for MACE and trial stopped early for increased bleeding in combo arm

A

AFIRE
(NEJM 2019)

29
Q

This trial showed enalapril in HFrEF w/ class IV sx lowered ACM vs placebo

A

CONSENSUS
(NEJM, 1987)

30
Q

This trial showed metoprolol succinate in symptomatic HFrEF lowered mortality and HHF vs placebo

A

MERIT-HF
(JAMA, 2000)

31
Q

This trial showed in symptomatic HF EF <25%, carvedilol reduced ACM + HHF vs placebo

A

COPERNICUS
(Circ 2002)

32
Q

This trial showed that in AMI with LVEF <40% but without CHF sx, captopril reduced ACM by 19% (NNT = 20) vs placebo.

A

SAVE
(NEJM 1992)

33
Q

This trial showed that in AMI with NYHA II-III CHF sx, ramipril reduced ACM by 27% vs placebo.

A

AIRE
(Lancet 1993)`

34
Q

This trial showed that in AMI with LVEF <40%, carvedilol did not significantly reduce ACM or CV hospitalizations vs placebo

A

CAPRICORN
(Lancet 2001)

35
Q

This trial showed that in AMI, IV followed by oral metoprolol for 15 days did not reduce MACE or death compared to placebo.

A

COMMIT
(Lancet 2005)

36
Q

This trial showed that in AMI with LVEF <35%, trandolapril (ACEi) reduced ACM by 22% (NNT 14) vs placebo.

A

TRACE
(NEJM 1995)

37
Q

This trial showed that in AMI with LVEF <40%, eplerenone decreased ACM by 15% vs placebo.

A

EPHESUS
(NEJM 2003)

38
Q
A
39
Q

This trial showed that in patients with left main disease low/intermediate SYNTAX score (<33), PCI was non-inferior to CABG for MACE (stroke, MI, death) at 3 years

A

EXCEL
(NEJM 2016)

40
Q

This trial showed that IVUS-guided (vs angiography alone) PCI in ACS decreased target vessel failure by 65% at 12 months.

A

ULTIMATE
(JACC 2018)

41
Q

This trial showed that OCT-guided (vs angio-guided) PCI of bifurcation lesions led to lower MACE.

A

OCTOBER
(NEJM 2023)

Cardiology (9 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions